新型PD-L1与CTLA-4双特异性抗体KN046在铂类化疗失败的非小细胞肺癌患者中的疗效与安全性:一项II期研究
这项多中心、开放标签II期试验评估KN046(靶向PD-L1和CTLA-4的双特异性抗体)在铂类化疗失败或不耐受的晚期非小细胞肺癌患者中的疗效与安全性。患者分别接受3 mg/kg(A组30例)或5 mg/kg(B组34例)KN046静脉给药,每2周一次。两组的客观缓解率分别为13.3%和14.7%,中位无进展生存期均为3.68个月,中位总生存期分别为19.70个月和13.04个月,≥3级治疗相关不良事件发生率为42.2%。
要点
- 3 mg/kg组和5 mg/kg组经盲态独立评审委员会评估的客观缓解率分别为13.3%和14.7%。
- 两组中位无进展生存期均为3.68个月,中位总生存期分别为19.70个月和13.04个月。
- ≥3级治疗相关不良事件发生率为42.2%,导致治疗中止的治疗相关不良事件发生率为14.1%。
核心结论
- 3 mg/kg和5 mg/kg的KN046对铂类化疗失败或不耐受的晚期非小细胞肺癌均显示出有前景的疗效和良好的安全性特征。
研究设计与样本
- 多中心、开放标签II期临床试验,纳入铂类化疗失败或不耐受的患者。
- KN046按3 mg/kg(A组30例)或5 mg/kg(B组34例)静脉给药,每2周一次。
- 主要终点为盲态独立评审委员会评估的客观缓解率。
主要发现
- 截至2021年8月31日,3 mg/kg组中位随访24.08个月(四分位距22.28,24.84),5 mg/kg组中位随访19.35个月(四分位距17.25,20.90)。
- 盲态独立评审委员会评估的客观缓解率在3 mg/kg组为13.3%,在5 mg/kg组为14.7%。
- 中位无进展生存期在3 mg/kg组为3.68个月(95%CI 3.22-7.29),在5 mg/kg组为3.68个月(95%CI 1.81-7.39)。
- 中位总生存期在3 mg/kg组为19.70个月(95.5%CI 15.44-未估计),在5 mg/kg组为13.04个月(95.5%CI 9.86-未估计)。
- 最常见的治疗相关不良事件为贫血(28.1%)、高血糖(26.7%)和输注相关反应(26.7%);≥3级治疗相关不良事件发生率为42.2%,导致治疗中止的治疗相关不良事件发生率为14.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate the efficacy and safety of KN046, a novel recombinant humanised antibody targeting PD-L1 and CTLA-4 in advanced non-small cell lung cancer (NSCLC) patients after failure or intolerance to platinum-based chemotherapy. METHODS: In this multi-centre, open-label phase II clinical trial, patients were enroled after failure or intolerance to platinum-based chemotherapy. KN046 at 3 mg/kg or 5 mg/kg was administered intravenously every 2weeks. The primary end-point was objective response rate (ORR) evaluated by a blinded independent review committee (BIRC). RESULTS: A total of 30 and 34 patients were included in the 3 mg/kg (cohort A) and 5 mg/kg (cohort B) cohorts. On 31st August 2021, the median follow-up duration was 24.08 months (interquartile [IQR], 22.28, 24.84) and 19.35months (IQR, 17.25, 20.90) in the 3 mg/kg and 5 mg/kg cohorts, respectively. BIRC-assessed ORRs were 13.3% and 14.7% in the 3 mg/kg and 5 mg/kg cohorts, respectively. Median progression-free survival was 3.68 (95% confidence interval [CI] 3.22-7.29) and 3.68 (95%CI 1.81-7.39) months, while overall survival was 19.70 (95.5%CI 15.44-not estimated [NE]) and 13.04 (95.5%CI 9.86-NE) months, respectively. The most common treatment-related adverse events (TRAEs) were anaemia (28.1%), hyperglycaemia (26.7%), and infusion-related reactions (26.7%). The incidence rates of grade ≥ 3 TRAEs and TRAEs leading to treatment discontinuation were 42.2% and 14.1%, respectively. CONCLUSIONS: Both 3 mg/kg and 5 mg/kg KN046 showed promising efficacy and favourable safety profile for advanced NSCLC after failure or intolerance to previous platinum-based chemotherapy. TRIAL REGISTRATION NUMBER: NCT03838848.
引用
- Xiong A, Li W, Li X, et al. Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. Eur J Cancer. 2023. PMID: 37393762. doi:10.1016/j.ejca.2023.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。